Du är här

2017-05-18

AstraZeneca: AstraZeneca to present scientific advancements from growing respiratory portfolio at the American Thoracic Soc...

Phase III ZONDA trial shows the potential of benralizumab to reduce or
discontinue the use of oral corticosteroids

AstraZeneca and its global biologics research and development arm,
MedImmune, will present new data from its growing respiratory
portfolio and pipeline at the 113th annual conference of the American
Thoracic Society (ATS) in Washington, DC, USA, 19-24 May 2017.

The breadth and depth of science behind AstraZeneca's growing
respiratory portfolio and pipeline are reflected in the 59 accepted
abstracts, including three oral presentations and 13 poster
discussions, which will focus on the unmet needs of asthma and
chronic obstructive pulmonary disease (COPD). A highlight will be the
reporting of data from two new trials from the WINDWARD programme for
benralizumab, AstraZeneca's most-advanced respiratory biologic
medicine.

Tom Keith-Roach, Vice President, Respiratory at AstraZeneca, said:
"The data being presented at the ATS conference will reflect our
commitment to advancing respiratory science in both inhaled
combinations and targeted biologics for unmet patient needs. We are
particularly excited to share the results of the ZONDA trial, looking
at the potential for benralizumab to reduce or discontinue oral
corticosteroids, which are a significant burden to many patients with
severe asthma."

Data from two Phase III trials of benralizumab in severe asthma

· The ZONDA trial evaluating oral corticosteroid (OCS)
dosage-sparing effects of benralizumab for patients with severe
asthma receiving high-dosage inhaled corticosteroid/long-acting
beta-2 agonist bronchodilator (ICS/LABA) and OCS (Abstract A4678).

· The GREGALE study assessing patient- and caregiver-reported
functionality, performance, and reliability of an accessorised
pre-filled syringe (APFS) used to administer benralizumab
subcutaneously in an at-home setting (Abstract A3194).

Advancing treatment options in COPD

· Evaluation of whether intensified treatment with Symbicort
(budesonide/formoterol fumarate dihydrate), an ICS/LABA, at the onset
of upper respiratory tract infection (URTI) could reduce
exacerbations in COPD (Abstract A7708).

· Data showing that Bevespi Aerosphere (glycopyrrolate 9
mcg/formoterol fumarate 4.8 mcg) inhalation aerosol, a fixed-dose
dual bronchodilator delivered in a pressurised metered-dose inhaler
(pMDI) and utilising innovative Co-Suspension™ Delivery Technology,
reduces the risk of first or sustained clinically-important
deteriorations versus placebo and monocomponent metered-dose inhalers
in COPD patients (Abstract A3594).

· Evaluation of the effects of Daxas (roflumilast), an oral PDE4
inhibitor, on exacerbations in patients with severe COPD and a
history of hospitalisation receiving inhaled combination therapy
(REACT/RE2SPOND) (Abstract A5724).

Evolving scientific understanding of disease modification

· Data highlighting breakthrough science aimed at potentially
modifying underlying biological drivers of respiratory diseases, with
a research focus on three areas:

· o Lung epithelium including new data on tezepelumab in adolescents (Abstract A5103) and further evidence of ENaC inhibition with AZD5634 in cystic fibrosis (Abstracts A6466, A7306).
· o Lung immunity including data on the role of dendritic cells in priming cytotoxic natural killer cells in COPD (Abstract A7354), new evidence of the modulation of CysLt and lipoxin production in human nasal polyps by LTC4S inhibition (Abstract A3169), and data improving the understanding of the host immune defence to viral infections driving exacerbations in asthma (Abstract A3178).
· o Lung regeneration including an abstract on the role of transglutaminase-2 in lung fibrosis (Abstract A2383) and new evidence of the role of extracellular matrix as a disease driver in COPD lung (Abstract A6296).

- ENDS -

NOTES TO EDITORS

About AstraZeneca in Respiratory Disease

Respiratory disease is one of AstraZeneca's main therapy areas, and
the Company has a growing portfolio of medicines that reached more
than 18 million patients in 2016. AstraZeneca's aim is to transform
asthma and COPD treatment through inhaled combinations at the core of
care, biologics for the unmet needs of specific patient populations,
and scientific advancements in disease modification.

The Company is building on a 40-year heritage in respiratory disease
and AstraZeneca's capability in inhalation technology spans both
pMDIs and dry powder inhalers, as well as the innovative
Co-SuspensionTMDelivery Technology. The Company's biologics include
benralizumab (anti-eosinophil, anti-IL-5r?), which has been accepted
for regulatory review in the US, EU and Japan, tralokinumab
(anti-IL-13), which is currently in Phase III, and tezepelumab
(anti-TSLP), which successfully achieved its Phase IIb primary
endpoint. AstraZeneca's research is focused on addressing underlying
disease drivers focusing on the lung epithelium, lung immunity and
lung regeneration.

About MedImmune

MedImmune is the global biologics research and development arm of
AstraZeneca, a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialisation of
small molecule and biologic prescription medicines. MedImmune is
pioneering innovative research and exploring novel pathways across
Oncology, Respiratory, Cardiovascular & Metabolic Diseases, and
Infection and Vaccines. The MedImmune headquarters is in
Gaithersburg, Md., one of AstraZeneca's three global R&D centres,
with additional sites in Cambridge, UK and Mountain View, CA. For
more information, please visit www.medimmune.com.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular & Metabolic
Diseases and Respiratory. The Company also is selectively active in
the areas of autoimmunity, neuroscience and infection. AstraZeneca
operates in over 100 countries and its innovative medicines are used
by millions of patients worldwide. For more information, please visit
www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Enquiries
Esra Erkal-Paler UK/Global +44 203 749 5638
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology +1 240 477 3771
Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970
Nick Stone Respiratory +44 203 749 5716
Christer Gruvris Autoimmunity, Neuroscience & Infection +44 203 749 5711
US toll free +1 866 381 7277

-----------------------------------------------------------
http://news.cision.com/se/astrazeneca/r/astrazeneca-to-present-scientifi...

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.